Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KMT2A - MLLT3 SRSF2 P95H||acute myeloid leukemia||sensitive||E7107||Preclinical||Actionable||In a preclinical study, E7107 treatment decreased tumor burden and prolonged survival in an isogenic mouse model of acute myeloid leukemia expressing KMT2A-MLLT3 (reported as MLL-AF9) and SRSF2 P95H, but not in a model expressing KMT2A-MLLT3 and wild-type SRSF2 (PMID: 27135740).||27135740|
|KMT2A - MLLT3 SRSF2 P95H||acute myeloid leukemia||sensitive||E7107||Preclinical - Cell culture||Actionable||In a preclinical study, murine KMT2A-MLLT3 ( reported as MLL-AF9)-driven acute myeloid leukemia cells expressing SRSF2 P95H demonstrated increased sensitivity to E7107 compared to cells expressing wild-type SRSF2 in culture (PMID: 31408619).||31408619|
|PubMed Id||Reference Title||Details|
|(27135740)||Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.||Full reference...|
|(31408619)||Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.||Full reference...|